295 related articles for article (PubMed ID: 4281483)
1. Drug treatment of diseases characterized by abnormal movements.
Marsden CD
Proc R Soc Med; 1973 Sep; 66(9):871-3. PubMed ID: 4281483
[No Abstract] [Full Text] [Related]
2. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
Chen JJ; Ondo WG; Dashtipour K; Swope DM
Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259
[TBL] [Abstract][Full Text] [Related]
3. [Use of haloperidol in the treatment of extrapyramidal compulsive movement].
Kivalo E; Weckman N
Nervenarzt; 1970 Nov; 41(11):567-9. PubMed ID: 4249744
[No Abstract] [Full Text] [Related]
4. [Haloperidol, reserpine, l-dopa and amantidine in the treatment of Huntington chorea (author's transl)].
Candelise L
Riv Patol Nerv Ment; 1976; 96(1):54-62. PubMed ID: 134449
[TBL] [Abstract][Full Text] [Related]
5. How best to address these common movement disorders.
Yaman A; Akdeniz M; Yaman H
J Fam Pract; 2011 Dec; 60(12):721-5. PubMed ID: 22163354
[No Abstract] [Full Text] [Related]
6. [Therapeutical approach to involuntary movements (author's transl)].
Allain H; Sabouraud O
Sem Hop; 1979 Feb 8-15; 55(5-6):262-4. PubMed ID: 219537
[TBL] [Abstract][Full Text] [Related]
7. Involuntary movement disorders.
Still CN
Neurol Clin; 1984 Feb; 2(1):71-89. PubMed ID: 6239089
[TBL] [Abstract][Full Text] [Related]
8. Tetrabenazine in the treatment of hyperkinetic movement disorders.
Kenney C; Jankovic J
Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307
[TBL] [Abstract][Full Text] [Related]
9. Tetrabenazine in the treatment of hyperkinetic movement disorders.
Jankovic J
Adv Neurol; 1983; 37():277-89. PubMed ID: 6574695
[No Abstract] [Full Text] [Related]
10. [Cholinergizing treatment in hyperkinesis].
Domzał T
Neurol Neurochir Pol; 1978; 12(3):257-61. PubMed ID: 150548
[TBL] [Abstract][Full Text] [Related]
11. Therapeutics of disordered movement.
Sears ES
Am Fam Physician; 1977 Sep; 16(3):145-54. PubMed ID: 143204
[TBL] [Abstract][Full Text] [Related]
12. Analysis of CYP2D6 genotype and response to tetrabenazine.
Mehanna R; Hunter C; Davidson A; Jimenez-Shahed J; Jankovic J
Mov Disord; 2013 Feb; 28(2):210-5. PubMed ID: 23280482
[TBL] [Abstract][Full Text] [Related]
13. [Hyperkinetic syndromes. Therapeutic trials].
Severini P; Pompili A; Pierini G
Riv Neurol; 1978; 48(2):242-8. PubMed ID: 276041
[TBL] [Abstract][Full Text] [Related]
14. [Haloperidol in the treatment of hyperkinetic syndromes].
Kivalo E; Weckman N
Duodecim; 1970; 86(3):129-32. PubMed ID: 5447422
[No Abstract] [Full Text] [Related]
15. [Monoamines and choreic syndromes].
Constantinidis J
Rev Neurol (Paris); 1972 Jul; 127(1):65-77. PubMed ID: 4272133
[No Abstract] [Full Text] [Related]
16. [Treatment of dyskinetic syndromes].
Werdelin LM; Pakkenberg H
Nord Med; 1994; 109(12):341-4. PubMed ID: 7997372
[TBL] [Abstract][Full Text] [Related]
17. Tardive dyskinesia.
Clyne KE; Juhl R
Am J Hosp Pharm; 1976 May; 33(5):481-6. PubMed ID: 1274963
[TBL] [Abstract][Full Text] [Related]
18. [Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements].
Giménez-Roldán S; Mateo D
Neurologia; 1989 Oct; 4(8):282-7. PubMed ID: 2534679
[TBL] [Abstract][Full Text] [Related]
19. [Trazodone in involuntary pathologic movements].
Rubino R; Provera P; Gilardengo P; Penza MT
Riv Neurol; 1984; 54(1):52-73. PubMed ID: 6718959
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic use of tiapride in movement disorders].
Mathé JF; Cler JM; Venisse JL
Sem Hop; 1978 May; 54(13-16):517-20. PubMed ID: 211595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
